Evaluating the cost-effectiveness of insulin detemir versus neutral protamine Hagedorn insulin in patients with type 1 or type 2 diabetes in the UK using a short-term modeling approach

References

• The Diabetes Control and Complications Trial Research Group The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial Diabetes 1995 44 8 968 983 7622004
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 1998 352 9131 837 853 9742976
   PubMed Web of Science ®Google Scholar
• Stratton IM Adler AI Neil HA Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ 2000 321 7258 405 412 10938048
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group Hypoglycemia in the diabetes control and complications trial Diabetes 1997 46 2 271 286 9000705
   PubMed Web of Science ®Google Scholar
• Frier BM Jensen MM Chubb BD Hypoglycaemia in adults with insulin-treated diabetes in the UK: self-reported frequency and effects Diabet Med 2016 33 8 1125 1132 26248501
   PubMed Web of Science ®Google Scholar
• UK Hypoglycaemia Study Group Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration Diabetologia 2007 50 6 1140 1147 17415551
   PubMed Web of Science ®Google Scholar
• Levy AR Christensen TL Johnson JA Utility values for symptomatic non-severe hypoglycaemia elicited from persons with and without diabetes in Canada and the United Kingdom Health Qual Life Outcomes 2008 6 73 18823555
   PubMed Web of Science ®Google Scholar
• Marrett E Stargardt T Mavros P Alexander CM Patient-reported outcomes in a survey of patients treated with oral antihyperglycaemic medications: associations with hypoglycaemia and weight gain Diabetes Obes Metab 2009 11 12 1138 1144 19758360
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence Technology appraisal guidance – No. 53 Guidance on the use of long-acting insulin analogues for the treatment of diabetes – insulin glargine. 2002 Available from: http://www.nice.org.uk/TA053 Accessed September 9, 2014
   Google Scholar
• Currie CJ Morgan CL Poole CD Sharplin P Lammert M McEwan P Multivariate models of health-related utility and the fear of hypoglycae-mia in people with diabetes Curr Med Res Opin 2006 22 8 1523 1534 16870077
   PubMed Web of Science ®Google Scholar
• Davis RE Morrissey M Peters JR Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetes Curr Med Res Opin 2005 21 9 1477 1483 16197667
   PubMed Web of Science ®Google Scholar
• Lundkvist J Berne C Bolinder B Jonsson L The economic and quality of life impact of hypoglycemia Eur J Health Econ 2005 6 3 197 202 15761775
   PubMedGoogle Scholar
• Nordfeldt S Ludvigsson J Fear and other diturbances of severe hypoglycemia in children and adolescents with type 1 diabetes mellitus J Pediatr Endocrinol Metab 2005 18 1 83 91 15679073
   PubMed Web of Science ®Google Scholar
• Matza LS Boye KS Yurgin N Utilities and disutilities for type 2 diabetes treatment-related attributes Qual Life Res 2007 16 7 1251 1265 17638121
   PubMed Web of Science ®Google Scholar
• Hermansen K Madsbad S Perrild H Comparison of the soluble basal insulin analog IDet with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal–bolus therapy Diabetes Care 2001 24 296 301 11213882
   PubMed Web of Science ®Google Scholar
• Vague P Selam JL Skeie S IDet is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart Diabetes Care 2003 26 590 596 12610006
   PubMed Web of Science ®Google Scholar
• Kølendorf K Ross GP Pavlic-Renar I IDet lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes Diabet Med 2006 23 7 729 735 16842476
   PubMed Web of Science ®Google Scholar
• Home P Bartley P Russell-Jones D IDet offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial Diabetes Care 2004 27 5 1081 1087 15111525
   PubMed Web of Science ®Google Scholar
• Robertson KJ Schoenle EM Gucev Z Benefits of IDet over NPH insulin in children and adolescents with type 1 diabetes: lower and more predictable fasting plasma glucose and lower risk of nocturnal hypoglycemia Diabet Med 2005 22 Suppl 2 45 15606690
   PubMed Web of Science ®Google Scholar
• De Leeuw Vague P Selam JL IDet used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin Diabetes Obes Metab 2005 7 73 82 15642078
   PubMed Web of Science ®Google Scholar
• Bartley PC Bogoev M Larsen J Philotheou A Long-term efficacy and safety of IDet compared to neutral protamine Hagedorn insulin in patients with type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial Diabet Med 2008 25 4 442 449 18387078
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in Health Long-acting insulin analogues for the treatment of diabetes mellitus: meta-analyses of clinical outcomes – update of CADTH technology report No. 92 COMPUS Rep 2008 2 1 Available from: http://www.cadth.ca/media/compus/reports/compus_Long-Acting-Insulin-Analogs-Report_Clinical-Outcomes.pdf Accessed March 7, 2018
   Google Scholar
• Gillespie P O’Shea E O’Hara MC Dinneen SF Irish DAFNE Study Group Cost effectiveness of group follow-up after structured education for type 1 diabetes: a cluster randomised controlled trial Trials 2014 15 227 24927851
   PubMed Web of Science ®Google Scholar
• Fajardo Montañana C Hernández Herrero C Rivas Fernández M Less weight gain and hypoglycaemia with once-daily IDet than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: the PREDICTIVE BMI clinical trial Diabet Med 2008 25 8 916 923 18959604
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence Type 1 diabetes in adults: diagnosis and Management Available from: https://www.nice.org.uk/guidance/ng17/resources/type-1-diabetes-in-adults-diagnosis-and-management-1837276469701 Accessed July 5, 2016
   Google Scholar
• Farmer A Wade A French DP Goyder E Kinmonth AL Neil A The DiGEM trial protocol – a randomised controlled trial to determine the effect on glycaemic control of different strategies of blood glucose self-monitoring in people with type 2 diabetes BMC Fam Pract 2005 6 25 15960852
   PubMedGoogle Scholar
• Farmer A Wade A Goyder E Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial BMJ 2007 335 7611 132 17591623
   PubMed Web of Science ®Google Scholar
• Evans M Khunti K Mamdani M Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries Health Qual Life Outcomes 2013 11 1 90 23731777
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence Type 2 diabetes (partially updated by CG87) (CG66) Appendix C Available from: http://www.nice.org.uk/guidance/cg66/resources/cg66-type-2-diabetes-full-guideline-appendices2 Accessed September 9, 2014
   Google Scholar
• Bagust A Beale S Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data Health Econ 2005 14 3 217 230 15386666
   PubMed Web of Science ®Google Scholar
• Lung TW Hayes AJ Hayen A Farmer A Clarke PM A meta-analysis of health state valuations for people with diabetes: explaining the variation across methods and implications for economic evaluation Qual Life Res 2011 20 10 1669 1678 21472392
   PubMed Web of Science ®Google Scholar
• Chubb B Tikkanen CK The cost of non-severe hypoglycaemia in Europe Value Health 2015 18 7 A611
   Web of Science ®Google Scholar
• Eliasson B Ekström N Bruce Wirta S Odén A Fard MP Svensson AM Metabolic effects of Basal or premixed insulin treatment in 5077 insulin-naïve type 2 diabetes patients: registry-based observational study in clinical practice Diabetes Ther 2014 5 1 243 254 24828137
   PubMed Web of Science ®Google Scholar
• Tajima N Iwamoto Y Kaku K Kawamori R Nishida T Kobayashi M Once-daily IDet added to oral antidiabetic drugs results in less weight gain and a trend for reduced hypoglycaemia in comparison to NPH insulin in Japanese patients with type 2 diabetes Diabetologia 2006 49 Suppl 1 609
   Google Scholar
• Donnelly LA Morris AD Frier BM Frequency and predictors of hypoglycaemia in type 1 and insulin-treated Type 2 diabetes: a population-based study Diabet Med 2005 22 6 749 755 15910627
   PubMed Web of Science ®Google Scholar
• Lauridsen JT Lønborg J Gundgaard J Jensen HH Diminishing marginal disutility of hypoglycaemic events: results from a time trade-off survey in five countries Qual Life Res 2014 23 9 2645 2650 24838908
   PubMed Web of Science ®Google Scholar
• Szypowska A Golicki D Groele L Pańkowska E Long-acting insulin analogue detemir compared with NPH insulin in type 1 diabetes: a systematic review and meta-analysis Pol Arch Med Wewn 2011 121 7–8 237 246 21878861
   PubMed Web of Science ®Google Scholar
• Philis-Tsimikas A Charpentier G Clauson P Ravn GM Roberts VL Thorsteinsson B Comparison of once-daily IDet with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes Clin Ther 2006 28 10 1569 1581 17157113
   PubMed Web of Science ®Google Scholar
• Hermansen K Davies M Derezinski T Martinez RG Clauson P Home P A 26-week, randomized, parallel, treat-to-target trial comparing IDet with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes Diabetes Care 2006 29 6 1269 1274 16732007
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard U Kristensen PL Beck-Nielsen H Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): a prospective, randomised, open-label, blinded-endpoint crossover trial Lancet Diabetes Endocrinol 2014 2 7 553 561 24794703
   PubMed Web of Science ®Google Scholar
• Drummond M Introducing economic and quality of life measurements into clinical studies Ann Med 2001 33 5 344 349 11491193
   PubMed Web of Science ®Google Scholar
• Walters SJ Brazier JE Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D Qual Life Res 2005 14 6 1523 1532 16110932
   PubMed Web of Science ®Google Scholar
• Vexiau P Mavros P Krishnarajah G Lyu R Yin D Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France Diabetes Obes Metab 2008 10 Suppl 1 16 24
   PubMed Web of Science ®Google Scholar
• Gschwend MH Aagren M Valentine WJ Cost-effectiveness of IDet compared with neutral protamine Hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in five European countries J Med Econ 2009 12 2 114 123 19545216
   PubMedGoogle Scholar
• Tunis SL Minshall ME Conner C Cost-effectiveness of IDet compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis Curr Med Res Opin 2009 25 5 1273 1284 19366302
   PubMed Web of Science ®Google Scholar
• Palmer AJ Lammert M Hermansen K Sundhedsøkonomiske konsekvenser af insulinanaloger til behandling af type 1-diabetes i Danmark [Health economic consequences of insulin analogues in the treatment of type 1 diabetes in Denmark] Ugeskr Laeger 2008 170 15 1250 1254 Danish 18433583
   PubMedGoogle Scholar